First line treatment failure: Predictive factors in a cohort of 863 Relapsing Remitting MS patients-Reference-Cited by-同舟云学术

First line treatment failure: Predictive factors in a cohort of 863 Relapsing Remitting MS patients

Published:2021-02 Issue: Volume:48 Page:102686
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Ayrignac Xavier,Bigaut Kevin,Pelletier Jean,de Seze Jérôme,Demortiere Sarah,Collongues Nicolas,Maarouf Adil,Pinna Frédéric^ORCID,Aouinti Safa,Carra Dallière Clarisse,Kremer Laurent,Charif Mahmoud,Picot Marie Christine,Labauge Pierre

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference35 articles.

1. Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor;Arrambide,2017

2. Predictors of long-term outcome in multiple sclerosis patients treated with interferon β;Bermel;Ann. Neurol.,2013

3. Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a clinically isolated syndrome;Brownlee;Mult. Scler. Houndmills Basingstoke Engl.,2017

4. Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis;Brownlee;Brain J. Neurol.,2019

5. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis;Cohen;N. Engl. J. Med.,2010

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prediction of disease activity and treatment failure in relapsing–remitting MS patients initiating daily oral DMTs;Multiple Sclerosis Journal;2024-03-29

2. Predictors of treatment switching in the Big Multiple Sclerosis Data Network;Frontiers in Neurology;2023-12-22

3. Epidemiology of demyelinating diseases in Mexico: A registry-based study;Multiple Sclerosis and Related Disorders;2023-07

4. Interleukins (IL-23 and IL-27) serum levels: Relationships with gene polymorphisms and disease patterns in multiple sclerosis patients under treatment with interferon and glatiramer acetate;Heliyon;2023-06

5. Paradigm shifts in multiple sclerosis management: Implications for daily clinical practice;Revue Neurologique;2023-04